Albireo Pharma (FRA:BDQM) Additional Paid-In Capital : €518.04 Mil(As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Additional Paid-In Capital?

Albireo Pharma's quarterly additional paid-in capital increased from Mar. 2022 (€438.82 Mil) to Jun. 2022 (€462.30 Mil) and increased from Jun. 2022 (€462.30 Mil) to Sep. 2022 (€518.04 Mil).

Albireo Pharma's annual additional paid-in capital increased from Dec. 2019 (€221.19 Mil) to Dec. 2020 (€375.22 Mil) and increased from Dec. 2020 (€375.22 Mil) to Dec. 2021 (€420.72 Mil).

Albireo Pharma Additional Paid-In Capital Historical Data

The historical data trend for Albireo Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Additional Paid-In Capital Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Additional Paid-In Capital

Get a 7-Day Free Trial

96.77

188.72

221.19

375.22

420.72

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Additional Paid-In Capital	Get a 7-Day Free Trial															401.51	420.72	438.82	462.30	518.04

Albireo Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Albireo Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines